DelveInsight’s, “Adenoid Cystic Carcinoma Pipeline Insight 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the Adenoid Cystic Carcinoma pipeline landscape. It covers the Adenoid Cystic Carcinoma pipeline drug profiles, including Adenoid Cystic Carcinoma clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Adenoid Cystic Carcinoma Emerging drugs, the Adenoid Cystic Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Adenoid Cystic Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Adenoid Cystic Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Adenoid Cystic Carcinoma clinical trials studies, Adenoid Cystic Carcinoma NDA approvals (if any), and product development activities comprising the technology, Adenoid Cystic Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Adenoid Cystic Carcinoma Pipeline Report
- DelveInsight’s Adenoid Cystic Carcinoma Pipeline analysis depicts a robust space with 5+ active players working to develop many treatment pipeline therapies.
- The leading Adenoid Cystic Carcinoma companies include SHEPHERD Therapeutics, Amgen, CureVac AG, Elevar Therapeutics, Actuate Therapeutics, Ayala Pharmaceuticals, Prelude Therapeutics, Merck Sharp & Dohme Corp., Lilly USA, LLC, Celgene Corporation, Eisai Inc., Bayer AG, CELLESTIA BIOTECH SA, Boston Biomedical, OncoMed Pharmaceuticals, Sumitomo Dainippon Pharma Co., Ltd. and others.
- Promising Adenoid Cystic Carcinoma pipeline therapies include Research program cancer therapeutics, AMG 232, CV8102, Rivoceranib, Elraglusib, AL101, PRT543, and others.
- The Adenoid Cystic Carcinoma Companies and academics are working to assess challenges and seek opportunities that could influence Adenoid Cystic Carcinoma R&D. The Adenoid Cystic Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Adenoid Cystic Carcinoma.
Request a sample and discover the recent breakthroughs happening in the Adenoid Cystic Carcinoma Pipeline landscape @ Adenoid Cystic Carcinoma Pipeline Outlook Report
Adenoid Cystic Carcinoma Overview
Adenoid cystic carcinoma (AdCC) is a rare form of adenocarcinoma, which is a broad term describing any cancer that begins in glandular tissues. In general, AdCC is found mainly in the head and neck region. It can occasionally occur in other locations in the body. AdCC most commonly occurs in the salivary glands, which consist of clusters of cells that secrete saliva scattered throughout the upper aerodigestive tract.
Recent Developmental Activities in the Adenoid Cystic Carcinoma Treatment Landscape
- In September 2021, Ayala Pharmaceuticals announced new preliminary clinical data from the 6mg cohort of its ongoing Phase 2 ACCURACY trial of AL101 for recurrent/metastatic Adenoid Cystic Carcinoma treatment harboring Notch-activating mutations.
- In February 2021, the US FDA granted Orphan Drug Designation to the small molecule tyrosine kinase inhibitor apatinib (Rivoceranib) for the treatment of rare cancer adenoid cystic carcinoma.
- Prelude Therapeutics is evaluating PRT543 in Phase I clinical trial in advanced solid tumors and select myeloid malignancies, including adenoid cystic carcinoma (ACC), myelofibrosis (MF), genomically-selected myelodysplastic syndrome (MDS), and homologous recombination deficient (HRD+) tumors.
- In November 2021, CureVac announced that Oncology Candidate CV8102 Showed Systemic Immune Response when studied in Phase I clinical trials.
- CV8102 is a single-stranded non-coding RNA optimized to maximize the activation of cellular receptors that normally detect viral pathogens entering the cells. It is currently being evaluated in Phase I clinical stage.
For further information, refer to the detailed Adenoid Cystic Carcinoma Drugs Launch, Adenoid Cystic Carcinoma Developmental Activities, and Adenoid Cystic Carcinoma News, click here for Adenoid Cystic Carcinoma Ongoing Clinical Trial Analysis
Adenoid Cystic Carcinoma Emerging Drugs Profile
- Rivoceranib : HLB
Rivoceranib is the first small-molecule tyrosine kinase inhibitor to be approved in gastric cancer under the name Apatinib in China (December 2014). Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), the primary pathway for tumor angiogenesis. VEGFR-2 inhibition is a clinically validated approach to limit tumor growth and disease progression. Rivoceranib has been studied in over 1,000 patients worldwide and was well tolerated in clinical trials with a comparable safety profile to other TKIs. Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy. Clinical studies are underway in multiple tumor types including, gastric cancer, hepatocellular carcinoma (combo w/camrelizumab), adenoid cystic carcinoma, and colorectal cancer (combo w/Lonsurf®). Orphan drug designations for rivoceranib have been granted in gastric cancer (U.S., EU, and South Korea) in adenoid cystic carcinoma (U.S.), and hepatocellular carcinoma (U.S.).
- Osugacestat : Ayala Pharmaceuticals
Ayala Pharmaceuticals investigational lead candidate (AL-101) is a novel, injectable, potent and selective small molecule gamma secretase inhibitor (GSI). AL101 is currently being studied in 2 ongoing Phase 2 trials. Our ACCURACY trial for the treatment of patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC), and our Phase 2 TENACITY trial for the treatment of patients with recurrent/metastatic triple negative breast cancer (R/M TNBC). The US Food and Drug Administration (FDA) granted Orphan Drug Designation and Fast Track Designation to AL101 for the potential treatment of ACC.
- Pembrolizumab : Merck & Co
Pembrolizumab is a fully humanized immunoglobulin G4/κ anti-PD-1 monoclonal antibody. Pembrolizumab has demonstrated robust antitumor activity and a favorable safety profile in multiple tumor types and is currently approved in >60 countries for 1 or more advanced malignancies, including in the United States for recurrent or metastatic head and neck squamous cell carcinoma that progressed on or after platinum-containing chemotherapy.
Adenoid Cystic Carcinoma Pipeline Therapeutics Assessment
There are approx. 5+ key companies which are developing the therapies for Adenoid Cystic Carcinoma. The companies which have their Adenoid Cystic Carcinoma drug candidates in the most advanced stage, i.e. phase II include, Ayala Pharmaceuticals.
Find out more about the Adenoid Cystic Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Adenoid Cystic Carcinoma Emerging Drugs @ Adenoid Cystic Carcinoma Treatment Landscape
Scope of the Adenoid Cystic Carcinoma Pipeline Report
- Coverage- Global
- Adenoid Cystic Carcinoma Companies- SHEPHERD Therapeutics, Amgen, CureVac AG, Elevar Therapeutics, Actuate Therapeutics, Ayala Pharmaceuticals, Prelude Therapeutics, Merck Sharp & Dohme Corp., Lilly USA, LLC, Celgene Corporation, Eisai Inc., Bayer AG, CELLESTIA BIOTECH SA, Boston Biomedical, OncoMed Pharmaceuticals, Sumitomo Dainippon Pharma Co., Ltd, and others.
- Adenoid Cystic Carcinoma Pipeline Therapies- Research program cancer therapeutics, AMG 232, CV8102, Rivoceranib, Elraglusib, AL101, PRT543, and others.
- Adenoid Cystic Carcinoma Pipeline Therapies- Product Type, Molecule Type, Mechanism of Action, Route of Administration
Dive deep into rich insights for drugs for Adenoid Cystic Carcinoma Pipeline Companies and Therapies, click here @ Adenoid Cystic Carcinoma Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Adenoid Cystic Carcinoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Adenoid Cystic Carcinoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Pre-Registration)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Last Stage Products (Phase III)
- Drug name : Company name
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Rivoceranib : HLB
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company Name
- Drug profiles in the detailed report…..
- Inactive Products
- Adenoid Cystic Carcinoma Key Companies
- Adenoid Cystic Carcinoma Key Products
- Adenoid Cystic Carcinoma – Unmet Needs
- Adenoid Cystic Carcinoma – Market Drivers and Barriers
- Adenoid Cystic Carcinoma – Future Perspectives and Conclusion
- Adenoid Cystic Carcinoma Analyst Views
- Adenoid Cystic Carcinoma Key Companies
- Appendix
Got Queries? Find out the related information on Adenoid Cystic Carcinoma Mergers and acquisitions, Adenoid Cystic Carcinoma Licensing Activities @ Adenoid Cystic Carcinoma Recent Trends, and Future Perspectives
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/